All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
On October 18, 2023, it was announced that brentuximab vedotin, a CD30-directed antibody-drug conjugate, in combination with doxorubicin, vinblastine and dacarbazine (AVD) received approval from the European Commission (EC) for the treatment of adult patients with previously untreated CD30+ Stage III Hodgkin lymphoma. This follows the recent positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on September 14, 2023.1
This approval is based on key findings from the randomized phase III ECHELON-1 trial (NCT01712490) comparing brentuximab vedotin plus AVD to doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). In 1,334 adult patients with previously untreated State III or IV classical Hodkin lymphoma.1 The study met its primary endpoint of modified progression-free survival as well as the secondary endpoint of overall survival (OS), demonstrating a statistically significant improvement in OS for the brentuximab vedotin plus AVD group.1 Additionally, the safety profile remained consistent with previous studies.1
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox